Showing 4091-4100 of 7033 results for "".
- Bimekizumab Phase 3 Data Show Superior Skin Clearance in Psoriasis vs. Placebo and Ustekinumabhttps://practicaldermatology.com/news/bimekizumab-phase-3-data-show-superior-skin-clearance-in-moderate-to-severe-psoriasis/2460421/UCB shared first presentations of data from the Phase 3 clinical development program of bimekizumab, its investigational IL-17A and IL-17F inhibitor, as part of a virtual session for the American Academy of Dermatology (AAD) 2020 Annual Meeting. Patients treated with bimekizumab achieved superior
- Sciton Unveils mJOULE Platform Featuring BBL HERO And MOXIhttps://practicaldermatology.com/news/sciton-unveils-mjoule-platform-featuring-bbl-hero-and-moxi/2460420/Sciton Inc. is rolling out their mJOULE dual-wavelength platform which includes a new fractional treatment, MOXI, and BBL HERO. MOXI delivers non-ablative laser energy to revitalize skin and BroadBand Light HERO (High Energy Rapid Output) allows practitioners to treat the entire body wi
- Alastin Skincare's INhance Post-Injection Serum Reduces Bruisinghttps://practicaldermatology.com/news/alastin-skincares-inhance-post-injection-serum-reduces-bruising/2460419/Alastin’s Skincare’s INhance Post-Injection Serum with TriHex Technology can help reduce post-injection bruising and swelling, according to a report inthe Journal of Drugs in Dermatology. In
- Asana BioSciences’ JAK/SYK Inhibitor Performs Well in Phase 2b Study of Hand Eczemahttps://practicaldermatology.com/news/asana-biosciences-jaksyk-inhibitor-performs-well-in-phase-2b-study-of-hand-eczema/2460409/Asana BioSciences’ investigational oral Janus kinase family (JAK) and spleen tyrosine kinase (SYK) inhibitor gusacitinib (ASN002) showed rapid and significant improvement in a phase 2b study of 97 adult patients with moderate-to-severe chronic hand eczema. The study was a randomiz
- ASLMS Names New Boardhttps://practicaldermatology.com/news/aslms-names-new-board/2460406/The American Society for Laser Medicine and Surgery (ASLMS) announced its new board during the Board of Directors meeting on April 30, 2020. Thomas E. Rohrer, MD is the new President of ASLMS is the world's largest professional organization dedicated to promoting research, education, and high
- Congrats: Dr. Paul Bergstresser Receives ASA’s David Martin Carter Mentor Awardhttps://practicaldermatology.com/news/congrats-dr-paul-bergstresser-receives-asas-david-martin-carter-mentor-award/2460401/Dr. Paul Bergstresser of UT Southwestern Medical Center in Dallas, Texas is the recipient of the American Skin Association’s (ASA) 2020 David Martin Carter Mentor Award Since 1989, ASA's David Martin Carter Mentor Award has honored members of the derma
- Hoth Therapeutics Obtains Full Licensing Rights for BioLexa Platform, Atopic Dermatitis Treatmenthttps://practicaldermatology.com/news/hoth-therapeutics-obtains-full-licensing-rights-for-biolexa-platform-atopic-dermatitis-treatment/2460397/Hoth Therapeutics, Inc. has obtained exclusive worldwide licensing rights to the BioLexa Platform, a proprietary, patented antimicrobial therapy focused on treating atopic dermatitis. This agreement serves as an extension to the previo
- AAD: Sixty Percent of Americans Have Gotten Sunburned So Badly Their Clothes Were Uncomfortablehttps://practicaldermatology.com/news/aad-sixty-percent-of-americans-have-gotten-sunburned-so-badly-their-clothes-were-uncomfortable/2460396/Most Americans say they have gotten a sunburn and admit it has impacted their day-to-day life, according to a recent AAD survey. Of those who have been sunburned, 60 percent said their sunburns made their clothes uncomfortable; 43 percent said they couldn’t sleep; and 21 percent said they w
- Cabaletta Bio Receives FDA Fast Track Designation for DSG3-CAART for the Treatment of mPVhttps://practicaldermatology.com/news/cabaletta-bio-receives-fda-fast-track-designation-for-dsg3-caart-for-the-treatment-of-mpv/2460383/The U.S. Food and Drug Administration (FDA) granted Cabaletta Bio’s DSG3-CAART (Desmoglein 3 Chimeric AutoAntibody Receptor T cells) Fast Track Designation for improving healing of mucosal blisters in patients with mPV. DSG3-CAART is designed to specifically target the cause of mP
- Bimini Health Tech’s Dermapose Access Office-Based Fat Harvesting System Scores FDA 510(k) clearancehttps://practicaldermatology.com/news/bimini-health-techs-dermapose-access-office-based-fat-harvesting-system-scores-fda-510k-clearance/2460368/Bimini Health Tech’s received US Food and Drug Administration (FDA) 510(k) clearance for its Dermapose Access, a novel fat harvesting system. Designed for office use, the launch of the Dermapose Access sy